Interplay of immunity and vitamin D: Interactions and implications with current IBD therapy

Current Medicinal Chemistry

Volumn 24, Issue 9, 2017, Pages 852-867

  Abdo, Joe ^a   Rai, Vikrant ^a   Agrawal, Devendra K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; CHEMOKINE; CYTOKINE; DEFENSIN; GROWTH FACTOR; IMMUNOMODULATING AGENT; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 6; MEMBRANE PROTEIN; TOLL LIKE RECEPTOR; VITAMIN D;

CELL COMPARTMENTALIZATION; CROHN DISEASE; GENOMICS; HUMAN; IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEOMICS; REVIEW; ULCERATIVE COLITIS; VITAMIN D DEFICIENCY; PHYSIOLOGY;

HUMANS; IMMUNITY; INFLAMMATORY BOWEL DISEASES; VITAMIN D;

EID: 85020193673     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666161026124951     Document Type: Review

References (127)

1. DeLuca, H.F. Chapter One - Vitamin D: Historical Overview; Vitamins & Hormones, USA, 2016, pp. 1-20.
2. Reich, K.M.; Fedorak, R.N.; Madsen, K.; Kroeker, K.I. Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review. World J. Gastroenterol., 2014, 20(17), 4934-4947.
3. Matricon, J.; Barnich, N.; Ardid, D. Immunopathogenesis of inflammatory bowel disease. Self Nonself, 2010, 1(4), 299-309.
4. Martineau, A.R.; Timms, P.M.; Bothamley, G.H.; Hanifa, Y.; Islam, K.; Claxton, A.P.; Packe, G.E.; Moore-Gillon, J.C.; Darmalingam, M.; Davidson, R.N.; Milburn, H.J.; Baker, L.V.; Barker, R.D.; Woodward, N.J.; Venton, T.R.; Barnes, K.E.; Mullett, C.J.; Coussens, A.K.; Rutterford, C.M.; Mein, C.A.; Davies, G.R.; Wilkinson, R.J.; Nikolayevskyy, V.; Drobniewski, F.A.; Eldridge, S.M.; Griffiths, C.J. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: A double-blind randomised controlled trial. Lancet, 2011, 377(9761), 242-250.
5. Khayyat, Y.; Attar, S.; Vitamin, D. Vitamin D deficiency in patients with irritable bowel syndrome: Does it exist? Oman Med. J., 2015, 30(2), 115-118.
6. Veldman, C.M.; Cantorna, M.T.; DeLuca, H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys., 2000, 374(2), 334-338.
7. Hewison, M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol. Metab. Clin. North Am., 2010, 39(2), 365-379.
8. Yu, X.P.; Hustmyer, F.G.; Garvey, W.T.; Manolagas, S.C. Demonstration of a 1,25-dihydroxyvitamin D3-responsive protein in human lymphocytes: immunologic crossreactivity and inverse regulation with the vitamin D receptor. Proc. Natl. Acad. Sci. USA, 1991, 88(19), 8347-8351.
9. Bhalla, A.K.; Amento, E.P.; Clemens, T.L.; Holick, M.F.; Krane, S.M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab., 1983, 57(6), 1308-1310.
10. Provvedini, D.M.; Tsoukas, C.D.; Deftos, L.J.; Manolagas, S.C. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science, 1983, 221(4616), 1181-1183.
11. Mann, E.R.; Li, X. Intestinal antigen-presenting cells in mucosal immune homeostasis: crosstalk between dendritic cells, macrophages and B-cells. World J. Gastroenterol., 2014, 20(29), 9653-9664.
12. Bscheider, M.; Butcher, E.C. Vitamin D immunoregulation through dendritic cells. Immunology, 2016, 148(3), 227-236.
13. Guerra, J.F.; Zasloff, M.; Lough, D.; Abdo, J.; Hawksworth, J.; Mastumoto, C.; Girlanda, R.; Island, E.; Shetty, K.; Kaufman, S.; Fishbein, T. Nucleotide oligomerization domain 2 polymorphisms in patients with intestinal failure. J. Gastroenterol. Hepatol., 2013, 28(2), 309-313.
14. Peyrin-Biroulet, L.; Chamaillard, M. NOD2 and defensins: Translating innate to adaptive immunity in Crohns disease. J. Endotoxin Res., 2007, 13(3), 135-139.
15. Grimm, M.C.; Pavli, P. NOD2 mutations and Crohns disease: are Paneth cells and their antimicrobial peptides the link? Gut, 2004, 53(11), 1558-1560.
16. Al Nabhani, Z.; Lepage, P.; Mauny, P.; Montcuquet, N.; Roy, M.; Le Roux, K.; Dussaillant, M.; Berrebi, D.; Hugot, JP.; Barreau, F. Nod2 deficiency leads to a specific and transmissible mucosa-associated microbial dysbiosis which is independent of the mucosal barrier defect. J Crohns Colitis, 2016, 10(12), 1428-1436.
17. Wang, T-T.; Dabbas, B.; Laperriere, D.; Bitton, A.J.; Soualhine, H.; Tavera-Mendoza, L.E.; Dionne, S.; Servant, M.J.; Bitton, A.; Seidman, E.G.; Mader, S.; Behr, M.A.; White, J.H. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J. Biol. Chem., 2010, 285(4), 2227-2231.
18. Dionne, S.; Calderon, M.R.; White, J.H.; Memari, B.; Elimrani, I.; Adelson, B.; Piccirillo, C.; Seidman, E.G. Differential effect of vitamin D on NOD2- and TLR-induced cytokines in Crohns disease. Mucosal Immunol., 2014, 7(6), 1405-1415.
19. Jäger, S.; Stange, E.F.; Wehkamp, J. Antimicrobial peptides and inflammatory bowel disease. In: Antimicrobial Peptides and Innate Immunity; Springer Basel: Basel, 2013; pp. 255-273.
20. Dupont, A.; Heinbockel, L.; Brandenburg, K.; Hornef, M.W. Antimicrobial peptides and the enteric mucus layer act in concert to protect the intestinal mucosa. Gut Microbes, 2014, 5(6), 761-765.
21. + lamina propria myeloid cells from intestinal transplant recipients with NOD2 mutations. Am. J. Transplant., 2012, 12(4), 992-1003.
22. Wehkamp, J.; Harder, J.; Weichenthal, M.; Mueller, O.; Herrlinger, K.R.; Fellermann, K.; Schroeder, J.M.; Stange, E.F. Inducible and constitutive beta-defensins are differentially expressed in Crohns disease and ulcerative colitis. Inflamm. Bowel Dis., 2003, 9(4), 215-223.
23. Leow, L.; Simpson, T.; Cursons, R.; Karalus, N.; Hancox, R.J. Vitamin D, innate immunity and outcomes in community acquired pneumonia. Respirology, 2011, 16(4), 611-616.
24. Eckmann, L.; Karin, M. NOD2 and Crohns disease: loss or gain of function? Immunity, 2005, 22(6), 661-667.
25. Raftery, T.; Martineau, A.R.; Greiller, C.L. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double-blind placebo-controlled study. United Eur. Gastroenterol. J., 2015, 3(3), 294-302.
26. Gombart, A.F.; Borregaard, N.; Koeffler, H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J., 2005, 19(9), 1067-1077.
27. Gombart, A.F. The vitamin D-antimicrobial peptide pathway and its role in protection against infection. Future Microbiol., 2009, 4(9), 1151-1165.
28. Chen, J.; Waddell, A.; Lin, Y-D.; Cantorna, M.T. Dysbiosis caused by vitamin D receptor deficiency confers colonization resistance to Citrobacter rodentium through modulation of innate lymphoid cells. Mucosal Immunol., 2015, 8(3), 618-626.
29. Liu, N.; Nguyen, L.; Chun, R.F.; Lagishetty, V.; Ren, S.; Wu, S.; Hollis, B.; DeLuca, H.F.; Adams, J.S.; Hewison, M. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology, 2008, 149(10), 4799-4808.
30. Raman, M.; Milestone, A.N.; Walters, J.R.; Hart, A.L.; Ghosh, S. Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer. Therap. Adv. Gastroenterol., 2011, 4(1), 49-62.
31. de Lange, K.M.; Barrett, J.C. Understanding inflammatory bowel disease via immunogenetics. J. Autoimmun., 2015, 64, 91-100.
32. Tao, Q.; Wang, B.; Zheng, Y.; Jiang, X.; Pan, Z.; Ren, J. Vitamin D prevents the intestinal fibrosis via induction of vitamin D receptor and inhibition of transforming growth factor-beta1/Smad3 pathway. Dig. Dis. Sci., 2015, 60(4), 868-875.
33. Qiu, W.; Wu, B.; Wang, X.; Buchanan, M.E.; Regueiro, M.D.; Hartman, D.J.; Schoen, R.E.; Yu, J.; Zhang, L. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J. Clin Invest., 2011, 121(5), 1722-1732.
34. Kiss, M.; Czimmerer, Z.; Nagy, L. The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology. J. Allergy Clin. Immunol., 2013, 132(2), 264-286.
35. Froicu, M.; Cantorna, M.T.; Bouma, G. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol., 2007, 8(1), 5.
36. Zhu, T.; Liu, T-J.; Shi, Y-Y.; Zhao, Q. Vitamin D/VDR signaling pathway ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis by inhibiting intestinal epithelial apoptosis. Int. J. Mol. Med., 2015, 35(5), 1213-1218.
37. Li, J.; Wei, Z.; Chang, X.; Cardinale, C.J.; Kim, C.E.; Baldassano, R.N.; Hakonarson, H. Pathway-based genome-wide association studies reveal the association between growth factor activity and inflammatory bowel disease. Inflamm. Bowel Dis., 2016, 22(7), 1540-1551.
38. Nunes, T.; Bernardazzi, C.; de Souza, H.S.; Nunes, T.; Bernardazzi, C.; de Souza, H.S. Cell death and inflammatory bowel diseases: apoptosis, necrosis, and autophagy in the intestinal epithelium. BioMed Res. Int., 2014, 2014, 218493.
39. Malloy, P.J.; Feldman, D. Inactivation of the human vitamin D receptor by caspase-3. Endocrinology, 2009, 150(2), 679-686.
40. Chen, P.; Li, Y.C.; Toback, F.G. AMP-18 Targets p21 to maintain epithelial homeostasis. PLoS One, 2015, 10(4), e0125490.
41. Chen, P.; Kartha, S.; Bissonnette, M.; Hart, J.; Toback, FG. AMP-18 facilitates assembly and stabilization of tight junctions to protect the colonic mucosal barrier. Inflamm Bowel Dis., 2012, 18, 1749-1759.
42. Liu, P.T.; Krutzik, S.R.; Modlin, R.L. Therapeutic implications of the TLR and VDR partnership. Trends Mol. Med., 2007, 13(3), 117-124.
43. Liu, P.T.; Stenger, S.; Li, H.; Wenzel, L.; Tan, B.H.; Krutzik, S.R.; Ochoa, M.T.; Schauber, J.; Wu, K.; Meinken, C.; Kamen, D.L.; Wagner, M.; Bals, R.; Steinmeyer, A.; Zügel, U.; Gallo, R.L.; Eisenberg, D.; Hewison, M.; Hollis, B.W.; Adams, J.S.; Bloom, B.R.; Modlin, R.L. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 2006, 311(5768), 1770-1773.
44. Basu, J.; Shin, DM.; Jo, EK. Mycobacterial signaling through toll-like receptors. Front Cell Infect Microbiol. 2012, 2:145.
45. Colonna, M.; Facchetti, F. TREM-1 (triggering receptor expressed on myeloid cells): a new player in acute inflammatory responses. J. Infect. Dis., 2003, 187(Suppl. 2), S397-S401.
46. Amatngalim, G.D.; Nijnik, A.; Hiemstra, P.S.; Hancock, R.E. Cathelicidin peptide LL-37 modulates TREM-1 expression and inflammatory responses to microbial compounds. Inflammation, 2011, 34(5), 412-425.
47. Kim, T-H.; Lee, B.; Kwon, E.; Choi, S.J.; Lee, Y.H.; Song, G.G.; Sohn, J.; Ji, J.D. Regulation of TREM-1 expression by 1,25-dihydroxyvitamin D3 in human monocytes/macrophages. Immunol. Lett., 2013, 154(1-2), 80-85.
48. Brynjolfsson, S.F.; Magnusson, M.K.; Kong, P.L. An antibody against triggering receptor expressed on myeloid cells 1 (TREM-1) dampens proinflammatory cytokine secretion by lamina propria cells from patients with IBD. Inflamm. Bowel Dis., 2016, 22(8), 1803-1811.
49. Singh, U.P.; Singh, N.P.; Murphy, E.A.; Price, R.L.; Fayad, R.; Nagarkatti, M.; Nagarkatti, P.S. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine, 2016, 77, 44-49.
50. Sanchez-Munoz, F.; Dominguez-Lopez, A.; Yamamoto-Furusho, J-K. Role of cytokines in inflammatory bowel disease. World J. Gastroenterol., 2008, 14(27), 4280-4288.
51. Hunter, C.A.; Jones, S.A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol., 2015, 16(5), 448-457.
52. Scheller, J.; Chalaris, A.; Schmidt-Arras, D.; Rose-John, S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta - Mol. Cell Res., 2011, 1813(5), 878-888.
53. Allocca, M.; Jovani, M.; Fiorino, G.; Schreiber, S.; Danese, S. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr. Drug Targets, 2013, 14(12), 1508-1521.
54. U.S. National Institutes of Health. ClinicalTrials.gov. clinicaltrials.gov. [Available from: http://clinicaltrials.gov/, 2013].
55. Kuhn, K.A.; Manieri, N.A.; Liu, T.C.; Stappenbeck, T.S. IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One, 2001, 9(12), e114195.
56. Stio, M.; Retico, L.; Annese, V.; Bonanomi, A.G. Vitamin D regulates the tight-junction protein expression in active ulcerative colitis. Scand. J. Gastroenterol., 2016, 51(10), 1193-1199.
57. Li, L.; Liu, Z.; Yang, X.; Yan, H.; Bao, S.; Fei, J. Bioluminescence imaging for IL-1β expression in experimental colitis. J. Inflamm. (Lond)., 2013, 10(1), 16.
58. Storek, K.M.; Monack, D.M. Bacterial recognition pathways that lead to inflammasome activation. Immunol. Rev., 2015, 265(1), 112-129.
59. Schroder, K.; Tschopp, J.; Agostini, L. The inflammasomes. Cell, 2010, 140(6), 821-832.
60. Chen, K.W.; Schroder, K. Antimicrobial functions of inflammasomes. Curr. Opin. Microbiol., 2013, 16(3), 311-318.
61. Church, L.D.; Cook, G.P.; McDermott, M.F. Primer: Inflammasomes and interleukin 1beta in inflammatory disorders. Nat. Clin. Pract. Rheumatol., 2008, 4(1), 34-42.
62. Calton, E.K.; Keane, K.N.; Newsholme, P.; Soares, M.J. The impact of vitamin D levels on inflammatory status: a systematic review of immune cell studies. PLoS One, 2015, 10(11), e0141770.
63. Verway, M.; Bouttier, M.; Wang, T-T.; Carrier, M.; Calderon, M.; An, B.S.; Devemy, E.; McIntosh, F.; Divangahi, M.; Behr, M.A.; White, J.H. Vitamin D induces interleukin-1β expression: Paracrine macrophage epithelial signaling controls M. tuberculosis infection. PLoS Pathog., 2013, 9(6), e1003407.
64. Khor, B.; Gardet, A.; Xavier, R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature, 2011, 474(7351), 307-317.
65. Vojinovic, J. Vitamin D receptor agonists anti-inflammatory properties. Ann. N. Y. Acad. Sci., 2014, 1317, 47-56.
66. Sommer, A.; Fabri, M. Vitamin D regulates cytokine patterns secreted by dendritic cells to promote differentiation of IL-22-producing T cells. PLoS One, 2015, 10(6), e0130395.
67. Barragan, M.; Good, M.; Kolls, J.K. Regulation of dendritic cell function by vitamin D. Nutrients, 2015, 7(9), 8127-8151.
68. Sadeghi, K.; Wessner, B.; Laggner, U.; Ploder, M.; Tamandl, D.; Friedl, J.; Zügel, U.; Steinmeyer, A.; Pollak, A.; Roth, E.; Boltz-Nitulescu, G.; Spittler, A. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol., 2006, 36(2), 361-370.
69. Wu, S.; Liao, A.P.; Xia, Y.; Li, Y.C.; Li, J.D.; Sartor, R.B.; Sun, J. Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine. Am. J. Pathol., 2010, 177(2), 686-697.
70. Zhang, Y.; Leung, D.Y.; Richers, B.N.; Liu, Y.; Remigio, L.K.; Riches, D.W.; Goleva, E. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J. Immunol., 2012, 188(5), 2127-2135.
71. Aranow, C. Vitamin D and the immune system. J. Investig. Med., 2011, 59(6), 881-886.
72. Dadaei, T.; Safapoor, M.H.; Asadzadeh Aghdaei, H.; Balaii, H.; Pourhoseingholi, M.A.; Naderi, N.; Zojaji, H.; Azimzadeh, P.; Mohammadi, P.; Zali, M.R. Effect of vitamin D3 supplementation on TNF-α serum level and disease activity index in Iranian IBD patients. Gastroenterol. Hepatol. Bed Bench, 2015, 8(1), 49-55.
73. Blaschitz, C.; Raffatellu, M. Th17 cytokines and the gut mucosal barrier. J. Clin. Immunol., 2010, 30(2), 196-203.
74. Sun, J. VDR/vitamin D receptor regulates autophagic activity through ATG16L1. Autophagy, 2016, 12(6), 1057-1058.
75. Simpson, H.L.; Campbell, B.J.; Rhodes, J.M. IBD: microbiota manipulation through diet and modified bacteria. Dig. Dis., 2014, 32(Suppl. 1), 18-25.
76. Karkeni, E.; Marcotorchino, J.; Tourniaire, F.; Astier, J.; Peiretti, F.; Darmon, P.; Landrier, J.F. Vitamin D limits chemokine expression in adipocytes and macrophage migration in vitro and in male mice. Endocrinology, 2015, 156(5), 1782-1793.
77. Meeker, S.; Seamons, A.; Paik, J.; Treuting, P.M.; Brabb, T.; Grady, W.M.; Maggio-Price, L. Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer. Cancer Res., 2014, 74(16), 4398-4408.
78. Riek, A.E.; Oh, J.; Bernal-Mizrachi, C. 1,25(OH)2 vitamin D suppresses macrophage migration and reverses atherogenic cholesterol metabolism in type 2 diabetic patients. J. Steroid Biochem. Mol. Biol., 2013, 136, 309-312.
79. Harishankar, M; Anbalagan, S; Selvaraj, P. Effect of vitamin D3 on chemokine levels and regulatory T-cells in pulmonary tuberculosis. Int Immunopharmacol., 2016, 34, 86-91.
80. Huang, F-C. The differential effects of 1,25-dihydroxyvitamin D3 on Salmonella-induced interleukin-8 and human beta-defensin-2 in intestinal epithelial cells. Clin. Exp. Immunol., 2016, 185(1), 98-106.
81. Glenn, A.J.; Fielding, K.A.; Chen, J.; Comelli, E.M.; Ward, W.E. Long-term vitamin D3 supplementation does not prevent colonic inflammation or modulate bone health in IL-10 knockout mice at young adulthood. Nutrients, 2014, 6(9), 3847-3862.
82. Zimmerman, N.P.; Vongsa, R.A.; Wendt, M.K.; Dwinell, M.B. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm. Bowel Dis., 2008, 14(7), 1000-1011.
83. Atreya, R.; Neurath, M.F. Chemokines in inflammatory bowel diseases. Dig. Dis., 2010, 28(3), 386-394.
84. Werner, L.; Guzner-Gur, H.; Dotan, I. Involvement of CXCR4/CXCR7/CXCL12 interactions in inflammatory bowel disease. Theranostics, 2013, 3(1), 40-46.
85. Keshav, S.; Vaňásek, T.; Niv, Y.; Petryka, R.; Howaldt, S.; Bafutto, M.; Rácz, I.; Hetzel, D.; Nielsen, O.H.; Vermeire, S.; Reinisch, W.; Karlén, P.; Schreiber, S.; Schall, T.J.; Bekker, P. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohns disease. PLoS One, 2013, 8(3), e60094.
86. Kalindjian, S.B.; Kadnur, S.V.; Hewson, C.A. Venkateshappa, C.; Juluri, C.; Kristam, R.; Kulkarni, B.; Mohammed, Z.; Saxena, R.; Viswanadhan, V.N.; Aiyori, J.; Muley, D. A new series of orally bioavailable chemokine receptor 9 (CCR9) antagonists; possible agents for the treatment of inflammatory bowel disease. J. Med. Chem., 2016, 59(7), 3098-3111.
87. Bendix-Struve, M.; Bartels, L.E.; Agnholt, J.; Dige, A.; Jørgensen, S.P.; Dahlerup, J.F. Vitamin D3 treatment of Crohns disease patients increases stimulated T cell IL-6 production and proliferation. Aliment. Pharmacol. Ther., 2010, 32(11-12), 1364-1372.
88. Bendix, M.; Dige, A.; Deleuran, B.; Dahlerup, J.F.; Jørgensen, S.P.; Bartels, L.E.; Husted, L.B.; Harsløf, T.; Langdahl, B.; Agnholt, J. Flow cytometry detection of vitamin D receptor changes during vitamin D treatment in Crohns disease. Clin. Exp. Immunol., 2015, 181(1), 19-28.
89. Cantorna, M.T.; Zhu, Y.; Froicu, M.; Wittke, A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am. J. Clin. Nutr., 2004, 80(6), 1717S-1720S.
90. Laverny, G.; Penna, G.; Vetrano, S.; Correale, C.; Nebuloni, M.; Danese, S.; Adorini, L. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol. Lett., 2010, 131(1), 49-58.
91. Triantafillidis, J.K.; Merikas, E.; Georgopoulos, F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des. Devel. Ther., 2011, 5, 185-210.
92. Armuzzi, A.; Gionchetti, P.; Daperno, M.; Danese, S.; Orlando, A.; Lia Scribano, M.; Vecchi, M.; Rizzello, F. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Dig. Liver Dis., 2016, 48(4), 360-370.
93. Shahidi, N.; Bressler, B.; Panaccione, R. Vedolizumab for the treatment of ulcerative colitis. Expert Opin. Biol. Ther., 2016, 16(1), 129-135.
94. Amiot, A.; Peyrin-Biroulet, L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap. Adv. Gastroenterol., 2015, 8(2), 66-82.
95. Nielsen, O.H.; Seidelin, J.B.; Ainsworth, M.; Coskun, M. Will novel oral formulations change the management of inflammatory bowel disease? Expert Opin. Investig. Drugs, 2016, 25(6), 709-718.
96. Furfaro, F.; Fiorino, G.; Allocca, M.; Gilardi, D.; Danese, S. Emerging therapeutic targets and strategies in Crohns disease. Expert Rev. Gastroenterol. Hepatol., 2016, 10(6), 735-744.
97. Ginard, D.; Khorrami, S.; Pérez-Carazo, L. Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study. Gastroenterol. Hepatol. (English Ed.), 2016, 39(6), 369-376.
98. Peyrin-Biroulet, L.; Van Assche, G.; Sturm, A.; Gisbert, J.P.; Gaya, D.R.; Bokemeyer, B.; Mantzaris, G.J.; Armuzzi, A.; Sebastian, S.; Lara, N.; Lynam, M.; Rojas-Farreras, S.; Fan, T.; Ding, Q.; Black, C.M.; Kachroo, S. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. Dig. Liver Dis., 2016, 48(6), 601-607.
99. Tougaard, P; Zervides, KA; Skov, S; Hansen, AK; Pedersen, A.E. Biologics beyond TNF-α inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders. Immunopharmacol. Immunotoxicol., 2016, 38(1), 29-38.
100. Shrestha, B. Minimally invasive surgery for inflammatory bowel disease: Current perspectives. World J. Gastrointest. Pharmacol. Ther., 2016, 7(2), 214-216.
101. Lima, C.A.; Lyra, A.C.; Rocha, R.; Santana, G.O. Risk factors for osteoporosis in inflammatory bowel disease patients. World J. Gastrointest. Pathophysiol., 2015, 6(4), 210-218.
102. Tapete, G; Almerigogna, V; Cozzi, A; Giannotta, M; Milani, S; Milla, M; Biagini, S. Hypovitaminosis D and low bone mineral density in inflammatory bowel disease patients. Int. J. Digest. Dis., 2016, 2, 1.
103. Hwang, C.; Hong, K. Other Micronutrient Deficiencies in Inflammatory Bowel Disease: From A to Zinc. In: Nutritional Management of Inflammatory Bowel Diseases; Springer International Publishing: Cham, 2016; pp. 65-101.
104. Bruzzese, V.; Zullo, A.; Piacchianti Diamanti, A. Vitamin D deficiency in patients with either rheumatic diseases or inflammatory bowel diseases on biologic therapy. Intern. Emerg. Med., 2016, 11(6), 803-807.
105. Reich, K.M.; Fedorak, R.N.; Madsen, K.; Kroeker, K.I. Role of Vitamin D in Infliximab-induced remission in adult patients with Crohns disease. Inflamm. Bowel Dis., 2016, 22(1), 92-99.
106. Santos-Antunes, J.; Nunes, A.C.; Lopes, S.; Macedo, G. The relevance of vitamin D and antinuclear antibodies in patients with inflammatory bowel disease under anti-TNF treatment: A prospective study. Inflamm. Bowel Dis., 2016, 22(5), 1101-1106.
107. Timmer, A.; Patton, P.H.; Chande, N.; McDonald, J.W.; MacDonald, J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2016, 5, CD000478.
108. Chaparro, M.; Gisbert, J.P. Maintenance therapy options for ulcerative colitis. Expert Opin. Pharmacother., 2016, 17(10), 1339-1349.
109. Cesarini, M; Festa, S; Papi, C. Methotrexate in Crohn's disease: A new face for an old drug?. Expert Rev. Gastroenterol. Hepatol., 2016, 13, 1-10.
110. Marcus, J.F.; Shalev, S.M.; Harris, C.A.; Goodin, D.S.; Josephson, S.A. Severe hypercalcemia following vitamin D supplementation in a patient with multiple sclerosis: A note of caution. Arch. Neurol., 2012, 69(1), 129-132.
111. De Ley, M.; de Vos, R.; Hommes, D.W.; Stokkers, P. Fish oil for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2007, 4, CD005986.
112. Lev-Tzion, R.; Griffiths, A.M.; Ledder, O.; Turner, D. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews; Lev-Tzion, R., Ed.; John Wiley & Sons, Ltd: Chichester, UK, 2014.
113. Isaacs, K.L.; Lochs, H.; Grimaldi, M.; Isaacs, K.L. Rifaximin in IBD: Is it time to beat back the bugs as induction therapy in Crohns disease? Inflamm. Bowel Dis., 2013, 19(2), 457-458.
114. Turner, D.; Levine, A.; Kolho, K-L.; Shaoul, R.; Ledder, O. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: A preliminary report. J. Crohns Colitis, 2014, 8(11), 1464-1470.
115. Flanagan, P.K.; Chiewchengchol, D.; Wright, H.L.; Edwards, S.W.; Alswied, A.; Satsangi, J.; Subramanian, S.; Rhodes, J.M.; Campbell, B.J. Killing of Escherichia coli by Crohns disease monocyte-derived macrophages and its enhancement by hydroxychloroquine and vitamin D. Inflamm. Bowel Dis., 2015, 21(7), 1499-1510.
116. Fu, N.; Wong, T. Clostridium difficile infection in patients with inflammatory bowel disease. Curr. Infect. Dis. Rep., 2016, 18(6), 19.
117. Wang, W.J.; Gray, S.; Sison, C.; Arramraju, S.; John, B.K.; Hussain, S.A.; Kim, S.H.; Mehta, P.; Rubin, M. Low vitamin D level is an independent predictor of poor outcomes in Clostridium difficile-associated diarrhea. Therap. Adv. Gastroenterol., 2014, 7(1), 14-19.
118. Ilan, Y. Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease. Clin. Transl. Immunol., 2016, 5(1), e60.
119. Kong, J.; Zhang, Z.; Musch, M.W. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. AJP Gastrointest. Liver Physiol., 2007, 294(1), G208-G216.
120. Zhao, H.; Zhang, H.; Wu, H.; Li, H.; Liu, L.; Guo, J.; Li, C.; Shih, D.Q.; Zhang, X. Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol., 2012, 12, 57.
121. Ham, M.; Longhi, M.S.; Lahiff, C.; Cheifetz, A.; Robson, S.; Moss, A.C. Vitamin D levels in adults with Crohns disease are responsive to disease activity and treatment. Inflamm. Bowel Dis., 2014, 20(5), 856-860.
122. Ananthakrishnan, A.N.; Khalili, H.; Higuchi, L.M.; Bao, Y.; Korzenik, J.R.; Giovannucci, E.L.; Richter, J.M.; Fuchs, C.S.; Chan, A.T. Higher predicted vitamin D status is associated with reduced risk of Crohns disease. Gastroenterology, 2012, 142(3), 482-489.
123. Ardesia, M.; Ferlazzo, G.; Fries, W.; Ardesia, M.; Ferlazzo, G.; Fries, W. Vitamin D and inflammatory bowel disease. BioMed Res. Int., 2015, 2015, 470805.
124. Chande, N.; Patton, P.H.; Tsoulis, D.J.; Thomas, B.S.; MacDonald, J.K. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohns disease. Cochrane Database Syst. Rev., 2015, 10, CD000067.
125. Tajika, M.; Matsuura, A.; Nakamura, T.; Suzuki, T.; Sawaki, A.; Kato, T.; Hara, K.; Ookubo, K.; Yamao, K.; Kato, M.; Muto, Y. Risk factors for vitamin D deficiency in patients with Crohns disease. J. Gastroenterol., 2004, 39(6), 527-533.
126. Leichtmann, G.A.; Bengoa, J.M.; Bolt, M.J.; Sitrin, M.D. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohns disease and intestinal resection. Am. J. Clin. Nutr., 1991, 54(3), 548-552.
127. Ulitsky, A.; Ananthakrishnan, A.N.; Naik, A.; Skaros, S.; Zadvornova, Y.; Binion, D.G.; Issa, M. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J. Parenter. Enteral Nutr., 2011, 35(3), 308-316.